Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
|07 Jun 2021||$0.1460||70.00%||Final||05 Jul 2021|
|26 Nov 2020||$0.0850||100.00%||Interim||16 Dec 2020|
|05 Jun 2020||$0.0610||70.00%||Final||06 Jul 2020|
|27 Nov 2019||$0.1150||30.00%||Interim||16 Dec 2019|
|03 Jun 2019||$0.1151||35.01%||Final||01 Jul 2019|
|29 Nov 2018||$0.1100||20.00%||Interim||18 Dec 2018|
|06 Jun 2018||$0.0900||40.00%||Final||02 Jul 2018|
|29 Nov 2017||$0.0800||40.00%||Interim||18 Dec 2017|
|07 Jun 2017||$0.0800||40.00%||Final||03 Jul 2017|
|05 Dec 2016||$0.0550||60.00%||Interim||21 Dec 2016|
|08 Jun 2016||$0.0600||40.00%||Final||01 Jul 2016|
|03 Dec 2015||$0.0751||25.03%||Interim||18 Dec 2015|
|09 Jun 2015||$0.1000||25.00%||01 Jul 2015|
|02 Dec 2014||$0.1100||10.00%||19 Dec 2014|
|11 Jun 2014||$0.2000||50.00%||Final||02 Jul 2014|
|07 Jun 2013||$0.2700||50.00%||Final||02 Jul 2013|
|01 Dec 2008||$0.5000||50.00%||Interim||17 Dec 2008|
|06 Jun 2008||$0.6000||50.00%||Final||01 Jul 2008|
|30 Nov 2007||$0.3500||50.00%||Interim||17 Dec 2007|
|06 Jun 2007||$0.4200||50.00%||Final||02 Jul 2007|
|29 Nov 2006||$0.2800||50.00%||Interim||15 Dec 2006|
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
ALS Ltd (ASX: ALQ) is a global testing, inspection and certification company. Although ALS' early history was focused on servicing the mineral exploration industry, the company has since broadened its exposure into a wide range of sectors including agriculture, pharmaceuticals and construction.
ALS, an initialism for Australian Laboratory Services, was established as a small chemical company in 1863. This company then went on to list on the local stock exchange in 1952. Today, ALS is a global company with operations in Asia, South America, North America, Africa, Europe and more recently, the Middle East. With this, the company employs more than 13,000 staff in over 65 countries.
Over the years, ALS shares have grown to sit comfortably within the S&P/ASX 200 Index (ASX: XJO) and now also offer ASX investors a stream of income in the form of dividends.
|22 Oct 2021||$13.71||$0.04||0.29%||658,569||$13.60||$13.75||$13.60|
|21 Oct 2021||$13.67||$-0.14||-1.01%||678,932||$13.86||$13.86||$13.63|
|20 Oct 2021||$13.81||$0.15||1.10%||1,057,531||$13.80||$13.94||$13.75|
|19 Oct 2021||$13.66||$0.05||0.37%||961,336||$13.79||$13.91||$13.66|
|18 Oct 2021||$13.61||$0.05||0.37%||571,440||$13.67||$13.74||$13.55|
|15 Oct 2021||$13.56||$0.21||1.57%||1,615,027||$13.47||$13.71||$13.30|
|14 Oct 2021||$13.35||$0.11||0.83%||1,142,932||$13.32||$13.41||$13.21|
|13 Oct 2021||$13.24||$0.05||0.38%||874,322||$13.15||$13.29||$13.14|
|12 Oct 2021||$13.19||$0.08||0.61%||1,089,809||$13.03||$13.20||$13.03|
|11 Oct 2021||$13.11||$-0.02||-0.15%||1,089,592||$12.74||$13.16||$12.74|
|08 Oct 2021||$13.13||$0.48||3.79%||1,465,556||$12.81||$13.23||$12.81|
|07 Oct 2021||$12.65||$0.24||1.93%||1,637,340||$12.60||$12.78||$12.52|
|06 Oct 2021||$12.41||$0.13||1.06%||1,262,809||$12.30||$12.47||$12.22|
|05 Oct 2021||$12.28||$-0.27||-2.15%||1,114,908||$12.19||$12.44||$12.10|
|04 Oct 2021||$12.55||$0.21||1.70%||532,158||$12.64||$12.69||$12.41|
|01 Oct 2021||$12.34||$-0.35||-2.76%||1,003,217||$12.42||$12.53||$12.29|
|30 Sep 2021||$12.69||$-0.01||-0.08%||1,212,211||$12.60||$12.80||$12.60|
|29 Sep 2021||$12.70||$0.02||0.16%||1,023,963||$12.58||$12.79||$12.44|
|28 Sep 2021||$12.68||$-0.17||-1.32%||730,255||$12.62||$12.82||$12.51|
|27 Sep 2021||$12.85||$0.10||0.78%||492,846||$12.79||$12.93||$12.75|
|24 Sep 2021||$12.75||$-0.20||-1.54%||423,222||$12.94||$13.00||$12.69|
|23 Sep 2021||$12.95||$0.23||1.81%||1,514,497||$12.86||$13.04||$12.82|
|01 Sep 2021||Raj Naran||Sell||79||$983,647|| |
As advised by the company. Sale of Ordinary shares to cover tax liability from vesting of shares under Company's LTI Plan.
|02 Aug 2021||Siddhartha Kadia||Buy||9||$116,968|| |
On-market trade. Average price
|28 Jul 2021||Raj Naran||Issued||112||$1,394,544|| |
Issue of securities. 380,538 - Performance Rights
|01 Jul 2021||Raj Naran||Cancelled||2||$36,020|| |
Cancellation of securities. 399,684 - Performance Rights & Service Rights
|01 Jul 2021||Raj Naran||Buy||131||$1,692,144|| |
Conversion of securities. Estimated Value
|01 Jul 2021||Raj Naran||Exercise||131||$1,692,144|| |
Conversion of securities. 268,102 - Performance Rights & Service Rights
|Mr Bruce John Phillips||Non-Executive DirectorNon-Executive Chairman||Aug 2015|| |
Mr Phillips have more than 35 years of technical, financial and managerial experience in the energy sector. He was previously Chairman of Platinum Capital Limited (October 2009 - June 2015) and a Non-Executive Director of AGL Energy Limited (August 2007 - September 2016) and Sunshine Gas Limited. In January 2019 Bruce was appointed as a Non-Executive Director and Chairman of Karoon Energy Limited. He is a member of the People Committee.
|Dr John Francis Mulcahy||Non-Executive Director||Feb 2012|| |
Dr Mulcahy is Chairman of Mirvac Group Limited (appointed November 2009 and Chair September 2013) and Orix Australia Corporation Limited, an unlisted public company (appointed March 2016), and Deputy Chairman of GWA Group Limited (appointed November 2010). He is also a current Non-Executive Director of various Zurich Australia Insurance subsidiaries. John was previously a director and Chairman of Coffey International Limited (September 2009 - January 2016). He is a former Guardian of the Future Fund of Australia and former Managing Director and Chief Executive Officer of Suncorp-Metway Limited. Prior to Suncorp, John held a number of senior executive roles at the Commonwealth Bank and Lend Lease Corporation. He is a member of the People Committee and Risk Committee.
|Mr Charlie Sartain||Non-Executive Director||Feb 2015|| |
Mr Sartain spent more than 30 years with MIM Holdings and then Xstrata plc after it acquired MIM. He led Xstrata's global copper business as Chief Executive of Xstrata Copper for nine years from 2004 and prior to that held senior executive positions with the company in Latin America and Australia. Charlie is currently a Non-Executive Director of OZ Minerals Limited, Chairman of the Advisory Board of the Sustainable Minerals Institute at the University of Queensland, and Chairman of the Board of Wesley Medical Research Ltd. His previous roles included Chairman of the International Copper Association, a Member of the Department of Foreign Affairs and Trade's Council on Australian Latin American Relations and a Director of Xstrata Schweiz Limited. He also served as a Non-Executive Director of Austin Engineering Limited, Goldcorp Inc., Newmont Corporation and as a two-term Member of the Senate of the University of Queensland. He was awarded an Honorary Doctorate in Engineering by the University of Queensland in 2019. He is Chairman of the Sustainability and Innovation Committee and Risk Committee.
|Ms Tonianne Dwyer||Non-Executive Director||Jul 2016|| |
Ms Dwyer has experience as a company director and executive working in finance, corporate strategy and mergers and acquisitions across a variety of sectors and international markets. She is an internationally experienced independent company director, having had a 25-year executive career in investment banking during which she held roles with Hambros Bank Limited and Societe General in the UK and Europe. She is Deputy Chancellor of the Senate of the University of Queensland and is on the Board of the Sir John Monash Foundation and Chief Executive Women. She is Chair of the People Committee and a member of the Sustainability and Innovation Committee.
|Ms Leslie A Desjardins||Non-Executive Director||Nov 2019|| |
Ms Desjardins has a background as a CFO and senior financial and governance professional in a range of large multinational and global businesses. She has commercial and financial governance expertise with large multinational public companies in North America, Canada and Australia each with extensive global operations. Her areas of expertise include CFO level executive and financial strategic leadership, M&A, corporate finance and treasury, governance, financial and tax compliance and enterprise risk management. Ms Desjardins is currently a Director, Audit Committee Chair, CSR/Risk Committee member with Ansell Limited and Director and Audit Committee Chair with Terry Fox Foundation, Canada. Previously, she served as a Board Director and Audit Committee member with AptarGroup. During her executive career, Ms Desjardins served as Executive VP and CFO at Amcor Limited, a global leader in packaging of food, beverage, pharmaceutical and tobacco products. Prior to Amcor Ltd, Ms Desjardins served in financial and corporate strategic positions with General Motors Corporation, including Chief Financial Officer GM Holden Australia, Controller GM North America, Executive Director Manufacturing Finance and Director GM North America Strategy and Planning. Ms Desjardins holds a Master of Science, Business with Massachusetts Institute of Technology, Sloan and a Bachelor of Industrial Administration, Finance with Kettering University. She is the Chair of the Risk Committee.
|Mr Raj Naran||Chief Executive OfficerManaging Director||Feb 2017|| |
Mr Naran founded e-Lab Analytical Inc which operated an environmental analytical testing business in Texas and Michigan until it was acquired by the Group in 2007. He was appointed to lead ALS USA Environmental business at that time and grew his role over the subsequent years to lead the global Life Sciences Division until his appointment to CEO in 2017. In December 2018 Raj was appointed as a Non-Executive Director to Redeye Apps Limited.
|Dr Siddhartha Kadia||Non-Executive Director||Jan 2019|| |
Dr Kadia was formerly President and CEO of EAG Laboratories, a global scientific testing company headquartered in San Diego. He has also been a Director of USA-listed companies Newport Corporation (NSDQ: NEWP) and Volcano Corporation (NSDQ: VOLC). He is currently a Non-Executive Director of BioSkryb Inc, Nuvasive, Inc (appointed February 2021) and other US-based companies including Isoplexis, ATS (Applied Technical Services), Overseers. Prior to EAG, Siddhartha served as President of the Life Sciences Division at Life Technologies Corporation (NSDQ: LIFE), a publicly traded Life Sciences tools company. Siddhartha was also a management consultant at McKinsey & Company where his work focused on various life sciences and healthcare related engagements. Siddhartha has lived and worked in the US, Japan, China and India and has more than 20 years of international experience as a company director, executive and technical leader in the Life Sciences and TIC (testing, inspection and certification) sectors. He is a member of the Sustainability and Innovation Committee and the People Committee.
|Mr Michael Paul Pearson||Company Secretary||Dec 2017|| |
|Luis Damasceno||Chief Financial Officer|| |
|Michael Paul Pearson||Company Secretary|| |
|Bruce McDonald||GM Geochemistry|| |
|Kristen Walsh||GM Industrial|| |
|Tim Kilmister||GM Life Sciences APAC|| |
|Andreas Jonsson||GM Life Sciences EMEA|| |
|HSBC Custody Nominees (Australia) Limited||125,867,258||26.09%|
|J P Morgan Nominees Australia Pty Limited||70,284,084||14.57%|
|Citicorp Nominees Pty Limited||47,739,469||9.90%|
|BNP Paribas Noms Pty Ltd <Drp>||22,979,364||4.76%|
|National Nominees Limited||20,223,337||4.19%|
|Citicorp Nominees Pty Limited <Colonial First State Inv A/C>||16,753,107||3.47%|
|BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C>||10,053,016||2.08%|
|Faircase Pty Ltd||7,803,731||1.62%|
|Australian Foundation Investment Company Limited||7,012,164||1.45%|
|Warbont Nominees Pty Ltd <Unpaid Entrepot A/C>||6,808,331||1.41%|
|Milton Corporation Limited||6,079,431||1.26%|
|Argo Investments Limited||5,104,023||1.06%|
|HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C>||4,675,865||0.97%|
|CS Third Nominees Pty Limited <Hsbc Cust Nom Au Ltd 13 A/C>||2,885,532||0.60%|
|BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C>||1,954,777||0.40%|
|Netwealth Investments Limited <Wrap Services A/C>||1,504,207||0.31%|
|Brispot Nominees Pty Ltd <House Head Nominee A/C>||1,444,389||0.30%|
|Ms Maryon Catherine Campbell <The Checkmate A/C>||1,372,574||0.29%|
|Avanteos Investments Limited <Encircle Ima A/C>||1,260,612||0.26%|
|EST Mrs Joyce Selina Hinds||1,193,227||0.25%|
ALS has announced a final dividend payment for FY20 of 6.1 cents per share, to be paid on 6 July. This dividend is 70% franked. No announcements have been made regarding its next dividend payment.
Yes, ALS offers a dividend reinvestment plan (DRP) as an alternative to receiving cash dividends on ALS ordinary shares. However, its DRP is not currently available for its final FY20 dividend payment.